Records
Browse every document routed through Assort Design.
Route Filters
A new, potential treatment for nonalcoholic steatohepatitis with fibrosis Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional F
One-line summary: A novel therapeutic approach inducing cytoglobin (CYGB) in hepatic stellate cells shows promise for treating nonalcoholic steatohepatitis (NASH) with fibrosis by mitigating oxidative DNA damage.
Citations: 4 · Risk: 1 High / 0 Medium / 0 Low
Potential leptin therapy for nonalcoholic steatohepatitis Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health
One-line summary: Leptin therapy using metreleptin shows promise in reducing liver fat and improving nonalcoholic steatohepatitis (NASH) in patients with low leptin levels, including those with partial lipodystrophy.
Citations: 4 · Risk: 1 High / 0 Medium / 0 Low
Researchers find possible genetic basis and mouse model for nonalcoholic steatohepatitis Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home Abo
One-line summary: Researchers identified the SRSF1 gene as a protective factor against DNA damage in liver cells, and its absence in a novel mouse model replicates all hallmarks of nonalcoholic steatohepatitis (NASH), proposing a new genetic basis for the disease.
Citations: 3 · Risk: 1 High / 0 Medium / 0 Low
Two new subtypes of MASH revealed with different risks and outcomes Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food Ne
One-line summary: Two new subtypes of metabolic dysfunction-associated steatohepatitis (MASH) with distinct risk profiles and outcomes have been identified, enabling personalized diagnosis and treatment.
Citations: 3 · Risk: 1 High / 0 Medium / 0 Low
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis June 20, 2025 PDF Version Positive recommendation based on res
One-line summary: Madrigal's Resmetirom (Rezdiffra™) has received positive CHMP opinion for treating MASH with fibrosis, demonstrating clinical benefit in fibrosis improvement and disease resolution, with European Commission decision expected August 2025.
Citations: 5 · Risk: 1 High / 1 Medium / 0 Low